Gene: NFKB1
Official Full Name: nuclear factor kappa B subunit 1provided by HGNC
Gene Summary: This gene encodes a 105 kD protein which can undergo cotranslational processing by the 26S proteasome to produce a 50 kD protein. The 105 kD protein is a Rel protein-specific transcription inhibitor and the 50 kD protein is a DNA binding subunit of the NF-kappa-B (NFKB) protein complex. NFKB is a transcription regulator that is activated by various intra- and extra-cellular stimuli such as cytokines, oxidant-free radicals, ultraviolet irradiation, and bacterial or viral products. Activated NFKB translocates into the nucleus and stimulates the expression of genes involved in a wide variety of biological functions. Inappropriate activation of NFKB has been associated with a number of inflammatory diseases while persistent inhibition of NFKB leads to inappropriate immune cell development or delayed cell growth. NFKB is a critical regulator of the immediate-early response to viral infection. Alternative splicing results in multiple transcript variants encoding different isoforms, at least one of which is proteolytically processed. [provided by RefSeq, Aug 2020]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
GP00560 | NFKB1 gRNA1-gRNA2 KO plasmid | NFKB1 | $850 | |||
GP00613 | NFKB1 gRNA3-gRNA4 KO plasmid | NFKB1 | $850 | |||
GP00614 | NFKB1 gRNA1-gRNA2 KO plasmid | NFKB1 | $850 | |||
KO00151 | NFKB1 Knockout cell line (U-87 MG) | Human | NFKB1 | 1:3~1:4 | Negative | Online Inquiry |
KO11035 | NFKB1 Knockout cell line (HeLa) | Human | NFKB1 | 1:3~1:6 | Negative | Online Inquiry |
KO11036 | NFKB1 Knockout cell line (HCT 116) | Human | NFKB1 | 1:2~1:4 | Negative | Online Inquiry |
KO11037 | NFKB1 Knockout cell line (HEK293) | Human | NFKB1 | 1:3~1:6 | Negative | Online Inquiry |
KO11038 | NFKB1 Knockout cell line (A549) | Human | NFKB1 | 1:3~1:4 | Negative | Online Inquiry |
NFKB1 Gene Knockout Cell Lines are genetically engineered cell lines where the NFKB1 gene has been disrupted, effectively removing its expression. The NFKB1 gene encodes a pivotal component of the NF-κB signaling pathway, a critical regulator of immune and inflammatory responses. By eliminating NFKB1, these cell lines provide researchers an invaluable tool for studying the role of NF-κB in various physiological and pathological processes, including tumorigenesis, immune responses, and neurodegenerative diseases.
The primary function of NFKB1 Gene Knockout Cell Lines is to allow for the examination of cellular responses in the absence of NF-κB signaling. This is achieved through CRISPR-Cas9 gene editing or other knockout techniques that create specific deletions in the genome. As a result, these cell lines facilitate investigations into the transcriptional programs governed by NF-κB, enabling scientists to dissect complex signaling networks and their implications in disease.
The scientific importance of these cell lines is underscored by their application in both research and clinical settings. They serve as a model to evaluate potential therapeutic targets, assess drug efficacy, and understand the mechanisms underlying various diseases, particularly in immunology and oncology. Researchers can leverage these knockout cell lines to validate hypotheses regarding the roles of NF-κB in inflammation and cancer biology, making them an essential resource in drug discovery and development.
Compared to alternative methodologies, NFKB1 Gene Knockout Cell Lines present distinct advantages, including higher specificity and reproducibility. Unlike transient knockdown techniques, these stable cell lines provide a more prolonged and consistent disruption of gene function, yielding reliable experimental results. Furthermore, they can be utilized in high-throughput screening applications, making them ideal for extensive pharmacological studies.
For researchers and clinicians seeking to deepen their understanding of NF-κB signaling and its implications in disease, NFKB1 Gene Knockout Cell Lines offer a powerful platform for discovery. Their ability to enable in-depth analyses of complex biological processes makes them invaluable assets in both basic and applied research settings. Our company is committed to providing high-quality, rigorously validated biological products, and our expertise in gene editing technologies ensures that you receive reliable and effective tools to advance your research objectives.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.